Corbus Pharmaceuticals Holdings Inc (CRBP)

Over the past six months, Corbus announced a proposed public offering, presented data for CRB-701 at the ESMO Congress, completed a Phase 1a study for CRB-913, and participated in healthcare conferences. They also reported Q4 and full-year 2025 financial results and announced alignment with the FDA on the registration path for CRB-701. The stock price has seen significant movement, with a 94.63% increase between April 7, 2025, and April 6, 2026. Over the last 12 months, the stock's price increased by 80.15%, and in the past month, it increased by 21.07%. However, over the past six months, the stock has experienced a -52.33% change.

As a clinical-stage biopharmaceutical company, Corbus Pharmaceuticals does not experience demand seasonality in the traditional sense, as its products are still in development and not yet commercialized.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious illnesses, particularly oncology and obesity. Their pipeline includes CRB-701, an antibody-drug conjugate for Nectin-4-expressing tumors; CRB-601, an anti-integrin monoclonal antibody; and CRB-913, a CB1 receptor inverse agonist for obesity.

Corbus Pharmaceuticals Holdings, Inc. is headquartered in Norwood, Massachusetts, United States. Clinical studies for product candidates like CRB-701 have included participants from both the U.S. and Europe.

Corbus Pharmaceuticals' brand reputation has been influenced by its clinical trial progress and financial updates. Positive data readouts for CRB-701 and CRB-913, along with FDA alignment for CRB-701, contribute positively. Analyst ratings, such as Mizuho Securities' "Buy" rating, suggest a positive outlook.

Corbus Pharmaceuticals Holdings, Inc. is owned by a mix of institutional shareholders and insiders. Institutional ownership stands at 74.67%, while insiders own 83.21%. Major institutional owners include Cormorant Asset Management, LP, Orbimed Advisors LLC, and Vanguard Group Inc. Cormorant Asset Management LP is the largest individual shareholder, owning 26.61% of the company.